- This accredited program is targeted to pharmacy technicians.
This CE activity was developed by The Rx Consultant, a publication of Continuing Education Network, Inc.
CE activities for Pharmacists and Pharmacy Technicians:
This continuing education (CE) activity meets the requirements of all state boards of pharmacy for approved continuing education hours. CE credit is automatically reported to CPE Monitor.
CE activities for Nurse Practitioners and Clinical Nurse Specialists:
This continuing education activity meets the requirements of:
The American Nurses Credentialing Center (ANCC) for formally approved continuing education (CE) hours, and CE hours of pharmacotherapeutics.
The American Academy of Nurse Practitioners Certification Program (AANPCP) for acceptable, accredited CE.
This is a pharmacotherapeutics/pharmacology CE activity.
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Requirements for CE Credit
- Describe at least 4 nondrug therapies that are used in the management of osteoarthritis (OA).
- Identify the generic name, brand name, and usual adult doses of medications commonly used for osteoarthritis management. Discuss an important safety concern with acetaminophen. Recognize common or potentially serious side effects of oral NSAIDs, tramadol, capsaicin, and duloxetine.
- Discuss 5 supplements commonly used for the management of OA, and identify a side effect or precaution for each.
Jelena Lewis, PharmD, PharmD
Brief Bio : Jelena Lewis, PharmD is an Assistant Professor of Pharmacy Practice at Chapman University School of Pharmacy. She is also a faculty-in-residence at St. Jude Heritage Medical Group where she provides chronic disease state management. se state management.
Disclosure : Dr. Lewis reports no financial relationship with the manufacturer(s) or provider(s) of any commercial product(s) or service(s) that appear in this issue.
Laressa Bethishou, PharmD, BCPS
Disclosure : Dr. Bethishou reports no financial relationship with the manufacturer(s) or provider(s) of any commercial product(s) or service(s) that appear in this issue.